Abbott Exercises its Option to Acquire Cephea Valve Technologie

 Abbott Exercises its Option to Acquire Cephea Valve Technologie

Abbott Exercises its Option to Acquire Cephea Valve Technologie

Shots:
  • Abbott to acquire Cephea Valve, in all stock transaction, with its heart valve replacement technology
  • The focus of the acquisition is to utilize Cephea’s technology in developing therapies for mitral valve disease while strengthening Abbott’s footprints in heart therapies
  • Cephea’s Technology develops an artificial valve, delivered through veins in the leg for patients in need of mitral valves replacements. Additionally, In 2009, Abbott acquired Evalve with its MitraClip technology for repairing leaky heart valves marketed in EU in 2008 and the US in 2013
Click here to read full press release/ article | Ref: Abbott | Image: Crain Chicago Business

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post